Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Sale Of US Oral Generics Unit Seems Unlikely

Executive Summary

The Swiss giant's Sandoz division is exploring options for its underperforming US oral generics unit but reports that it may be considering a sale of the latter go against Novartis' previous comments and observers are struggling to see the rationale behind such a move.

Advertisement

Related Content

Novartis Sees The Light And Plumps For Alcon Spin-Off
Novartis Sees The Light And Plumps For Alcon Spin-Off
Novartis Sees The Light And Plumps For Alcon Spin-Off
What Will Novartis Do With $13bn Cash Pile From GSK?
Sandoz's Less Frequently Dosed Copaxone Generic Glatopa Hits Teva Two Months Early
Three Strikes For Generic Advair With An FDA CRL For Sandoz

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100420

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel